Browsing by Author "Dumic, Igor (57212525843)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer(2019) ;Lalosevic, Milica Stojkovic (57218133245) ;Markovic, Aleksandra Pavlovic (24438035400) ;Stankovic, Sanja (7005216636) ;Stojkovic, Mirjana (58776160500) ;Dimitrijevic, Ivan (59595303500) ;Vujacic, Irena Radoman (57208718001) ;Lalic, Daria (57206903158) ;Milovanovic, Tamara (55695651200) ;Dumic, Igor (57212525843)Krivokapic, Zoran (55503352000)Background. Systemic inflammation in colorectal cancer (CRC) may be reflected by neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV). This study was designed to investigate the efficiency of preoperative NLR, PLR, and MVP as a tool for the assessment of tumor characteristics in newly diagnosed patients with CRC. Patients and Methods. For 300 patients and 300 healthy volunteers, complete blood counts with automated differential counts were performed. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count; PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count. The diagnostic performance of NLR, PLR, and MVP was estimated by ROC curve. Results. ROC curve analysis showed high diagnostic efficacy of NLR and PLR in CRC patients with cut-off values of 2.15 (AUC = 0 790, 95% CI 0.736-0.884, Se = 74 1%, and Sp = 73%) and 123 (AUC = 0 846, 95% CI 0.801-0.891, Se = 73 5%, and Sp = 80%) compared to healthy controls, respectively. The diagnostic efficacy of three combined markers was superior compared with individual markers (AUC = 0 904, 95% CI 0.812-0.989, Se = 96%, and Sp = 70%). Conclusion. NRL, PLR, and MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally combined all together have stronger diagnostic efficacy. © 2019 Milica Stojkovic Lalosevic et al. - Some of the metrics are blocked by yourconsent settings
Publication Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer(2019) ;Lalosevic, Milica Stojkovic (57218133245) ;Markovic, Aleksandra Pavlovic (24438035400) ;Stankovic, Sanja (7005216636) ;Stojkovic, Mirjana (58776160500) ;Dimitrijevic, Ivan (59595303500) ;Vujacic, Irena Radoman (57208718001) ;Lalic, Daria (57206903158) ;Milovanovic, Tamara (55695651200) ;Dumic, Igor (57212525843)Krivokapic, Zoran (55503352000)Background. Systemic inflammation in colorectal cancer (CRC) may be reflected by neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV). This study was designed to investigate the efficiency of preoperative NLR, PLR, and MVP as a tool for the assessment of tumor characteristics in newly diagnosed patients with CRC. Patients and Methods. For 300 patients and 300 healthy volunteers, complete blood counts with automated differential counts were performed. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count; PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count. The diagnostic performance of NLR, PLR, and MVP was estimated by ROC curve. Results. ROC curve analysis showed high diagnostic efficacy of NLR and PLR in CRC patients with cut-off values of 2.15 (AUC = 0 790, 95% CI 0.736-0.884, Se = 74 1%, and Sp = 73%) and 123 (AUC = 0 846, 95% CI 0.801-0.891, Se = 73 5%, and Sp = 80%) compared to healthy controls, respectively. The diagnostic efficacy of three combined markers was superior compared with individual markers (AUC = 0 904, 95% CI 0.812-0.989, Se = 96%, and Sp = 70%). Conclusion. NRL, PLR, and MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally combined all together have stronger diagnostic efficacy. © 2019 Milica Stojkovic Lalosevic et al. - Some of the metrics are blocked by yourconsent settings
Publication Quality of Life in Patients with Primary Biliary Cholangitis: A Single-Center Experience in Serbia(2020) ;Milovanovic, Tamara (55695651200) ;Popovic, Dusan (37028828200) ;Stojkovic Lalosevic, Milica (57218133245) ;Dumic, Igor (57212525843) ;Dragasevic, Sanja (56505490700)Milosavljević, Tomica (7003788952)Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease, predominantly affecting middle-aged women, which may progress to end-stage liver disease. We aimed to assess the quality of life (QoL) in patients with PBC given that social, economic, and geographical factor also influence QoL. Methods: This study included patients with diagnosed PBC according to the European Association for the Study of the Liver guidelines, who were treated for at least 6 months in order to allow adequate time for the initial burden of symptoms to subside. We used the PBC-40 questionnaire validated in the Serbian language. Results: The mean total PBC-40 score was 89.4 ± 29.3. The overall frequency of moderate and severe involvement in each domain was as follows: 84.9% (n = 107) in "Symptoms,"29.3% (n = 36) in "Itch,"76.4% (n = 97) in "Fatigue,"58.1% (n = 72) in "Cognitive,"77.2% (n = 98) in "Social,"and 70.9% (n = 90) in "Emotional."There was a statistically significant negative correlation of disease duration and albumin score with the Emotional domain score. Furthermore, this domain showed a significant positive correlation with the Mayo score. Conclusion: The present study demonstrates that patients with PBC have significant impairment in QoL with fatigue being the most prevalent symptom. The Social and Emotional domains were also significantly affected in these individuals, particularly in patients with peripheral edema who exhibited worse QoL that those who were euvolemic. © 2020 S. Karger AG, Basel. Copyright: All rights reserved.
